NCT05204290终止1 期
A Pilot Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab in Patients With High-Grade Epidural Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Number of Participants Completing Stereotactic Body Radiation Therapy (SBRT) and One Cycle of Pembrolizumab
研究概览
简要总结
The purpose of this research study is to find out what effects (good and bad) Pembrolizumab and radiosurgery have on participants with high-grade epidural disease of the spine.
详细描述
Primary Objective: To determine the feasibility of patients completing stereotactic body radiation therapy and at least one (1) cycle of Pembrolizumab.
Secondary Objectives:
- Evaluate the radiographic response after decompressive stereotactic body radiation therapy and Pembrolizumab by calculating the improvement in thecal sac patency.
- Evaluate accrual rate.
- Evaluate pain relief.
- Evaluate quality of life.
- Evaluate cumulative incidence of adverse events.
- Evaluate potential correlative blood biomarkers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologic diagnosis of cancer, confirmed by review of pathology report.
- •Epidural disease seen on MRI at 1 vertebral level or 2 contiguous vertebral level.
- •Synchronous and metachronous sites of disease allowed.
- •Patient with expected life span of ≥ 3 months.
- •Deemed eligible for stereotactic body radiation therapy and pembrolizumab after multi-disciplinary review. The multi-disciplinary review will be conducted virtually via our Spinal Oncology Group (SPOG) Wake Forest e-mail listserv. Members of the distribution list include neurosurgeons, orthopedic surgeons, interventional radiologists, radiologists, and radiation oncologists. This group meets monthly via Webex and in the interim, cases are routinely reviewed using encrypted emails via the listserv. Because we will not be able to wait for a month meeting to enroll patients on study, we anticipate needing to review these patients via the listserv. The electronic review will serve as documentation of multi-disciplinary review.
- •Patients currently being treated with pembrolizumab or anticipated to receive at least one dose of pembrolizumab within six weeks after finishing stereotactic body radiation therapy.
- •Patients who have received prior immunotherapy are allowed.
- •Age equal or greater than
- •Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).
排除标准
- •Prior radiation therapy or surgery to index lesion.
- •Patients with lymphoma, multiple myeloma, germinomas, seminomas, Wilm's tumors, and Ewing's sarcomas will be excluded.
- •Muscle strength of ≤ 3 out of 5 on neurologic exam that correlates with level of the involved spinal cord.
- •Retropulsed compression fracture.
- •Patients with a contraindication to pembrolizumab.
- •Patients may not be receiving any other investigational agents.
- •Patients with symptomatic, brain metastases, as determined by the study PI, that could confound the neurologic exam, should be excluded.
- •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant women are excluded from this study because both radiation and pembrolizumab can be harmful to the developing fetus. Because there is an unknown but potential risk for adverse events, pregnant women are not allowed to participate in this study, in nursing infants secondary to treatment of the mother with pembrolizumab, breastfeeding should be discontinued.
研究组 & 干预措施
Stereotactic Body Radiotherapy and Pembrolizumab Treatment
Experimental
MRI scans of your spine (before treatment, 2 months after treatment, and 6 months after treatment) and immunotherapy with Pembrolizumab
干预措施: Stereotactic Body Radiation Therapy (Radiation)
Stereotactic Body Radiotherapy and Pembrolizumab Treatment
Experimental
MRI scans of your spine (before treatment, 2 months after treatment, and 6 months after treatment) and immunotherapy with Pembrolizumab
干预措施: Blood draws (Other)
Stereotactic Body Radiotherapy and Pembrolizumab Treatment
Experimental
MRI scans of your spine (before treatment, 2 months after treatment, and 6 months after treatment) and immunotherapy with Pembrolizumab
干预措施: Pembrolizumab (Drug)
结局指标
主要结局
Number of Participants Completing Stereotactic Body Radiation Therapy (SBRT) and One Cycle of Pembrolizumab
时间窗: At Day 5 and up to cycle 1 (Day 22)
A 95% confidence interval for the primary outcome, the feasibility of patients completing stereotactic body radiation therapy and at least one cycle of Pembrolizumab, will be calculated.
次要结局
- Incidences of Compression Fractures(1 month after intervention and 6 months after intervention)
- Changes in Plasma(At baseline, 2 months and 6 months after intervention)
- Change in Thecal Sac Patency - (Percentage)(At baseline, at 2 months and 6 months after intervention)
- Accrual Rate(Every 2 months, up to 6 months)
- Number of Participants Experiencing Improvement in Pain - Numeric Pain Rating Scale (NPRS)(At baseline, at 2 months and 6 months after intervention)
- Quality of Life - European Organization for Research and Treatment of Cancer QoL Group Bone Metastases Module (QLQ-BM22)(At baseline, at 2 months and 6 months after intervention)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) CancerGastric CancerEsophageal CancerNCT02954536Memorial Sloan Kettering Cancer Center37
进行中（未招募）
1 期
Breast Cancer Study of Preoperative Pembrolizumab + RadiationBreast CancerNCT03366844Stephen Shiao66
招募中
1 期
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSLLymphomaPrimary Central Nervous System LymphomaNCT06475235Dana-Farber Cancer Institute15
终止
3 期
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China ExtensionProstatic NeoplasmsNCT04907227Merck Sharp & Dohme LLC81
已完成
3 期
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)Prostatic NeoplasmsNCT03834506Merck Sharp & Dohme LLC1,030